23 May 2013
Keywords: sirolimus, impresses, ph, wet, amd, trial, macusight
Article | 03 March 2008
MacuSight, a USA-based developer of therapeutics for the treatment of
severe ocular conditions, says that it has seen positive data ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
3 March 2008
22 May 2013
© 2013 thepharmaletter.com